---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-080498"
form_type: "8-K"
ticker: "NKTR"
cik: "0000906709"
company_name: "NEKTAR THERAPEUTICS"
filed_at: "2022-12-16T23:59:59+00:00"
generated_at: "2026-06-21T03:50:43.542853+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Nektar amends bylaws for universal proxy rules, DGCL updates, and remote meetings

## Summary
- Board approved bylaw amendments effective Dec 15, 2022, to comply with SEC universal proxy rules and recent DGCL changes.
- Stockholder nominations now require representation of intent to solicit at least 67% voting power.
- Company may hold meetings solely by remote communication; proxy cards for board nominees must be white.
- Enhanced disclosure requirements for stockholder proposals and director nominations added.
- Proxies for disqualified or withdrawn nominees to be treated as abstentions.

## SEC filing metadata
- accession: 0001213900-22-080498
- form_type: 8-K
- ticker: NKTR
- cik: 0000906709
- company_name: NEKTAR THERAPEUTICS
- filed_at: 2022-12-16T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/906709/000121390022080498/0001213900-22-080498-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/906709/000121390022080498/ea170222-8k_nektartherap.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-080498
- JSON: https://secwatch.observer/filing/0001213900-22-080498.json
- Plain text: https://secwatch.observer/filing/0001213900-22-080498.txt

## Key facts
- Governance Changes
  NEKTAR THERAPEUTICS: Amended the Amended and Restated Bylaws to reflect changes in DGCL, adopt universal proxy rules, and enhance stockholder proposal requirements (effective 2022-12-15).
  - Change: bylaw amendment
  - Effective: 2022-12-15
  source text: On December 15, 2022, in connection with the new Securities and Exchange Commission rules and changes to the Securities Exchange Act of 1934, as amended (the “Exchange Act”) regarding universal proxy cards, certain recent changes to the Delaware General Corporation Law (the “DGCL”), and a periodic review of corporate governance matters, the Board of Directors (the “Board”) of Nektar Therapeutics (the “Company”), approved amendments to the Company’s Amended and Restated Bylaws (the “Bylaws”), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/906709/000121390022080498/0001213900-22-080498-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.